抗GII.4型人诺如病毒VP1的DNA疫苗诱导阻断抗体产生和T细胞应答
研究构建了表达GII.4型人诺如病毒主要结构蛋白VP1的CMV/R载体DNA疫苗,体外转染HEK293T细胞成功表达VP1蛋白;小鼠经肌内或皮内免疫后均诱发了针对GII.4 VP1的阻断抗体和T细胞应答,作者认为该构建体是有前景的DNA疫苗候选。
要点
- 构建了表达GII.4型人诺如病毒VP1的CMV/R载体DNA疫苗。
- 体外转染HEK293T细胞成功表达VP1蛋白。
- 小鼠肌内或皮内免疫均诱发阻断抗体和T细胞应答。
核心结论
- 作者认为CMV/R-GII.4 HuNoV VP1是有前景的抗GII.4型人诺如病毒DNA疫苗候选。
研究设计与样本
- 研究构建表达GII.4型人诺如病毒主要结构蛋白VP1的CMV/R载体(CMV/R-GII.4 HuNoV VP1)。
- 体外转染HEK293T细胞检测VP1表达,并以小鼠肌内或皮内免疫评估免疫原性。
主要发现
- CMV/R-GII.4 HuNoV VP1转染HEK293T细胞后成功表达VP1蛋白。
- 小鼠肌内或皮内免疫该构建体后诱发针对GII.4 HuNoV VP1的阻断抗体产生。
- 小鼠肌内或皮内免疫该构建体后激活针对GII.4 HuNoV VP1的T细胞应答。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human noroviruses (HuNoVs) are highly contagious and a leading cause of epidemics of acute gastroenteritis worldwide. Among the various HuNoV genotypes, GII.4 is the most prevalent cause of outbreaks. However, no vaccines have been approved for HuNoVs to date. DNA vaccines are proposed to serve as an ideal platform against HuNoV since they can be easily produced and customized to express target proteins. In this study, we constructed a CMV/R vector expressing a major structural protein, VP1, of GII.4 HuNoV (CMV/R-GII.4 HuNoV VP1). Transfection of CMV/R-GII.4 HuNoV VP1 into human embryonic kidney 293T (HEK293T) cells resulted in successful expression of VP1 proteins in vitro. Intramuscular or intradermal immunization of mice with the CMV/R-GII.4 HuNoV VP1 construct elicited the production of blocking antibodies and activation of T cell responses against GII.4 HuNoV VP1. Our collective data support the utility of CMV/R-GII.4 HuNoV VP1 as a promising DNA vaccine candidate against GII.4 HuNoV.
引用
- Kim NE, Kim MJ, Park BJ, et al. A DNA vaccine against GII.4 human norovirus VP1 induces blocking antibody production and T cell responses. Vaccine. 2024. PMID: 38320930. doi:10.1016/j.vaccine.2024.01.090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。